Holen Sie sich die Stockscreener-App
3.98
150.31%
2.39
Vorhandelsmarkt:
2.82
-1.16
-29.15%
Schlusskurs vom Vortag:
$1.59
Offen:
$1.58
24-Stunden-Volumen:
32.47M
Relative Volume:
44.81
Marktkapitalisierung:
$225.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-131.52M
KGV:
-2.236
EPS:
-1.78
Netto-Cashflow:
$-107.56M
1W Leistung:
+132.75%
1M Leistung:
+170.75%
6M Leistung:
+348.50%
1J Leistung:
+220.97%
1-Tages-Spanne:
$1.43
$4.22
1-Wochen-Bereich:
$1.43
$4.22
52-Wochen-Spanne:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Firmenname
Prelude Therapeutics Inc
Sektor
Branche
Telefon
(302) 467-1280
Adresse
175 INNOVATION BOULEVARD, WILMINGTON
Vergleichen Sie PRLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
3.98 | 89.99M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-19 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Eingeleitet | Jefferies | Buy |
| 2022-03-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-02-28 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-04-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-09 | Eingeleitet | Barclays | Overweight |
| 2020-11-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-20 | Eingeleitet | BofA Securities | Buy |
| 2020-10-20 | Eingeleitet | Goldman | Neutral |
| 2020-10-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prelude Therapeutics Inc Aktie (PRLD) Neueste Nachrichten
Prelude Therapeutics stock climbs after exclusive JAK2 option deal with Incyte - Investing.com India
A Look at Prelude Therapeutics Inc (PRLD) Shares in the Recent Past Indicates Growth - setenews.com
Prelude Therapeutics Announces Strategic Updates: Prioritizes JAK2V617F and KAT6A Programs, Pauses SMARCA2 Development and Secures $60 Million from Incyte Option Agreement - Quiver Quantitative
Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus - Stock Titan
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Yahoo Finance
Can Prelude Therapeutics Incorporated stock hit analyst price targetsMarket Weekly Review & Safe Capital Growth Tips - newser.com
Will Prelude Therapeutics Incorporated stock deliver shareholder valueSwing Trade & Safe Investment Capital Preservation Plans - newser.com
What institutional flow reveals about Prelude Therapeutics IncorporatedMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Prelude Therapeutics (PRLD) Projected to Post Earnings on Wednesday - Defense World
Prelude Therapeutics Spikes: Can The Pipeline Keep Up? - RTTNews
Prelude Therapeutics (NASDAQ:PRLD) and CytoDyn (OTCMKTS:CYDY) Financial Analysis - Defense World
Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Prelude Therapeutics (PRLD) to Present Preclinical Findings at A - GuruFocus
Is Prelude Therapeutics Incorporated stock ready for a breakoutQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting - Yahoo Finance
Pattern recognition hints at Prelude Therapeutics Incorporated upsideJuly 2025 Market Mood & Stepwise Swing Trade Plans - newser.com
What to do if you’re stuck in Prelude Therapeutics IncorporatedJuly 2025 Weekly Recap & Safe Swing Trade Setups - newser.com
How Prelude Therapeutics Incorporated stock reacts to oil pricesJuly 2025 Movers & High Accuracy Swing Entry Alerts - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 2025Quarterly Portfolio Summary & Weekly Setup with High ROI Potential - newser.com
Volume spikes in Prelude Therapeutics Incorporated stock – what they meanJuly 2025 Recap & Technical Pattern Based Buy Signals - newser.com
Can Prelude Therapeutics Incorporated stock maintain operating marginsJuly 2025 Snapshot & Consistent Income Trade Recommendations - newser.com
Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsPortfolio Performance Report & High Return Trade Guides - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipelineBear Alert & AI Enhanced Trade Execution Alerts - newser.com
Prelude Therapeutics Shares Surge on Analyst Optimism and Upcoming Earnings - AD HOC NEWS
Prelude Therapeutics Incorporat (PRLD) stock forecast and price target - Yahoo! Finance UK
What sentiment indicators say about Prelude Therapeutics Incorporated stockWatch List & Verified Technical Trade Signals - newser.com
Using flow based indicators on Prelude Therapeutics IncorporatedDip Buying & Safe Entry Zone Tips - newser.com
How to build a custom watchlist for Prelude Therapeutics Incorporated2025 Investor Takeaways & Weekly Momentum Picks - newser.com
Prelude Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
What machine learning models say about Prelude Therapeutics IncorporatedTrend Reversal & Reliable Trade Execution Plans - newser.com
Exit strategy if you’re trapped in Prelude Therapeutics IncorporatedJuly 2025 Action & Risk Controlled Swing Trade Alerts - newser.com
How Prelude Therapeutics Incorporated stock performs in interest rate cyclesInflation Watch & Free Expert Verified Stock Movement Alerts - newser.com
Real time alert setup for Prelude Therapeutics Incorporated performanceInsider Selling & Free Daily Entry Point Trade Alerts - newser.com
Prelude Therapeutics Incorporated (PRLD) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Prelude Therapeutics Incorporated (PRLD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Finanzdaten der Prelude Therapeutics Inc-Aktie (PRLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):